# AFLAC Incorporated

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/AFLAC Incorporated).

## Overview

Aflac Incorporated sells supplemental health and life insurance designed to pay cash benefits directly to policyholders when covered events occur, helping households manage out-of-pocket medical and income-disruption costs. The company operates through two core reporting segments—Aflac Japan and Aflac U.S.—and serves millions of policyholders in Japan and the United States. In the U.S., distribution is built around worksite/employee-benefits channels supported by a large agent and broker force, while Japan is centered on long-duration health and life products. Earnings and capital generation are tightly linked to underwriting performance (morbidity, mortality, persistency) and to investment portfolio results, including interest rates, credit spreads, and hedging outcomes.

## Products & services

• Supplemental accident insurance
• Supplemental disability insurance
• Critical care (cancer/critical illness/hospital intensive care)
• Hospital indemnity insurance
• Dental and vision (via Aflac Benefits Solutions platform)
• Supplemental life insurance
• Third-party administration / benefits platform services (ABS)

- **Aflac Japan supplemental health and life** (70%) — Supplemental health and life policies sold in Japan, supported by long-duration liabilities and investment portfolios.
- **Aflac U.S. supplemental health** (22%) — U.S. worksite and voluntary benefits including accident, disability, critical care and hospital indemnity products.
- **Aflac U.S. dental and vision** (5%) — Dental and vision offerings delivered through Aflac Benefits Solutions and employer benefits channels.
- **Aflac U.S. life** (3%) — Supplemental life insurance products sold primarily through employer-related distribution.

- Supplemental accident insurance
- Supplemental disability insurance
- Critical care (cancer/critical illness/hospital intensive care)
- Hospital indemnity insurance
- Dental and vision (via Aflac Benefits Solutions platform)
- Supplemental life insurance
- Third-party administration / benefits platform services (ABS)

## Customers

Aflac’s end customers are individual policyholders who buy supplemental coverage to add cash benefits on top of major medical insurance, particularly to address deductibles, copays, and income gaps. In the U.S., purchasing is often mediated by employers and brokers in the worksite/employee-benefits channel, where Aflac’s agent force enrolls employees and services accounts. In Japan, customers typically purchase long-duration health and life products through local distribution partners and channels, with value tied to product features, premium rates, and claims service. Across both markets, persistency and claims experience (morbidity/mortality) are key drivers of customer economics and product pricing discipline.

- **Japan individual policyholders** (primary) — Buy supplemental health and life policies for cash benefits and long-term protection; drives the majority of in-force liabilities and investment backing.
- **U.S. worksite employees (voluntary benefits)** (primary) — Purchase accident, disability, critical care and hospital indemnity through payroll/worksite enrollment to cover out-of-pocket medical and income risks.
- **U.S. employers (benefits sponsors)** (secondary) — Select Aflac offerings to broaden employee benefits and improve retention, enabling access to employee groups and enrollment events.
- **Brokers and independent agents** (secondary) — Distribute and service Aflac products; commissions and producer capacity influence sales momentum and account penetration.
- **U.S. dental/vision members via ABS platform** (emerging) — Enroll in dental and vision plans administered through Aflac Benefits Solutions as part of employer-sponsored benefits.

- Employees buying voluntary/worksite supplemental benefits for cash protection
- Employers offering Aflac as part of benefits packages to enhance coverage
- Brokers and agents placing Aflac products and managing enrollments
- Japanese individual policyholders seeking long-duration health/life coverage
- Policyholders valuing fast claims service and predictable cash benefits

## Geography

Aflac’s insurance operations are concentrated in two countries: Japan and the United States, reported as Aflac Japan and Aflac U.S. This geographic mix creates exposure to Japanese yen translation and to Japan-specific interest-rate dynamics, which management highlights through measures such as U.S. dollar-denominated investment income excluding foreign currency impact. The company also operates reinsurance activities including Aflac Re Bermuda Ltd., which is regulated under the Bermuda Insurance Act and has dividend and capital constraints. Geographic concentration means regulatory, competitive, and macro conditions in Japan and the U.S. can disproportionately affect sales, persistency, and investment results. The U.S. business is supported by a nationwide agent/broker footprint, while Japan is supported by local distribution and a large investment portfolio backing long-duration liabilities.

- Two reportable segments: Aflac Japan and Aflac U.S.
- Japan exposure includes yen FX translation and local rate environment
- U.S. operations include multi-state insurance regulation and approvals
- Bermuda reinsurance entity (Aflac Re) faces solvency/dividend limits
- Geographic concentration heightens sensitivity to Japan/U.S. competition

## Strategy

Aflac’s strategy centers on sustaining demand for supplemental products by competing on product features, premium rates, platforms, value-added services, and claims service, while leveraging brand awareness and distribution capabilities. In the U.S., management tracks agent productivity (weekly producer equivalents) as a leading indicator of sales capacity, reflecting a focus on distribution strength and enrollment execution. The company also emphasizes portfolio management and asset allocation—investing in fixed maturities, loan receivables, and growth assets (including public equities and limited partnership alternatives)—to support policy liabilities and earnings. Given competitive pressure from major medical carriers bundling and discounting supplemental products, Aflac’s differentiation relies on specialized supplemental design and service model rather than broad medical bundling. Ongoing investment and hedging activities are integral to managing yield, capital, and volatility across both segments.

- **Expand and optimize U.S. distribution capacity** (short-term) — Sales momentum depends on active producer capacity and enrollment execution in worksite channels.
- **Maintain product competitiveness in supplemental lines** (medium-term) — Bundling/discounting by major medical carriers increases price and feature competition in supplemental segments.
- **Portfolio management and asset allocation to support liabilities** (medium-term) — Investment income and capital are key drivers of insurance economics and can be volatile with rates/spreads.

- Strengthen U.S. worksite distribution via agent/broker productivity
- Differentiate supplemental products through features and claims service
- Use platforms/value-added services to support enrollment and retention
- Active asset allocation to balance yield, credit risk, and liquidity
- Manage FX and market volatility impacts on Japan segment results

## Risks

Aflac’s results are sensitive to market risks because large investment portfolios back policy liabilities; changes in interest rates and credit spreads can drive realized/unrealized gains and losses, impairments, and capital/dividend capacity at regulated subsidiaries. Competitive risk is elevated in the U.S. as major medical carriers seek entry into supplemental segments and use bundling and discounting to gain share, which can pressure pricing and persistency. The company disclosed a June 2025 cybersecurity incident involving exfiltration of sensitive personal and health information in its U.S. business, creating potential for remediation costs, litigation, regulatory actions, and reputational harm. As an insurer, Aflac also faces underwriting risks (morbidity, mortality, persistency) and regulatory constraints on intercompany transactions and subsidiary dividends. Concentration in Japan and the U.S. adds exposure to country-specific regulation, macro conditions, and foreign currency impacts on reported results.

- **Interest rate risk on investment portfolios backing liabilities** [high] — Significant rate changes can drive realized losses, impairments, unrealized swings and liquidity impacts, affecting results and capital.
- **Credit spread risk and market volatility affecting portfolio values** [high] — Spread widening can create unrealized losses and reduce adjusted capital/dividend capacity; volatility complicates valuation.
- **Cybersecurity incident with exfiltration of sensitive data (June 2025)** [critical] — May lead to remediation costs, higher insurance premiums, litigation, regulatory investigations/enforcement and reputational damage.

- Interest rate moves can cause impairments and capital/liquidity stress
- Credit spread widening can reduce portfolio values and dividend capacity
- U.S. competition from major medical carriers bundling supplemental lines
- Cybersecurity incident (June 2025) with data exfiltration and legal risk
- Underwriting risk from morbidity, mortality and persistency assumptions
- Regulatory limits on subsidiary dividends and affiliate transactions
- FX translation and hedging effectiveness risk for Japan segment reporting

## Accounting

Aflac’s reported earnings can be materially affected by valuation of investments and derivatives, including fair value changes, credit losses, and the accounting for certain derivative and foreign currency activities that management may exclude from adjusted earnings. Insurance accounting relies heavily on actuarial estimates for liabilities for future policy benefits and on assumptions used in deferred acquisition costs (DAC), making results sensitive to changes in morbidity, mortality, persistency, discount rates, and other inputs. The company identifies valuation of investments and derivatives, DAC, future policy benefit liabilities, and income taxes as critical accounting estimates, noting these judgments affect a large portion of reported assets and liabilities. Because the business is regulated, statutory accounting and solvency frameworks (including Bermuda BSCR/EBS for Aflac Re) can constrain dividend capacity and influence capital management decisions. Investors should also expect quarter-to-quarter volatility from net investment gains/losses (e.g., securities transactions, equity fair value changes) even when underlying underwriting trends are stable.

- **Valuation of investments and derivatives (including credit losses)** — Volatility in net earnings and shareholders’ equity
- **Liabilities for future policy benefits (actuarial estimates)** — Direct effect on insurance liabilities and earnings
- **Deferred acquisition costs (DAC)** — Timing of expense recognition and segment profitability

- Fair value and credit loss accounting for investment portfolios
- Derivatives and foreign currency activities can drive earnings volatility
- Actuarial estimates for future policy benefits are highly judgmental
- Deferred acquisition costs (DAC) depend on persistency/assumptions
- Income tax estimates and uncertain positions affect net earnings
- Adjusted earnings exclude certain investment gains/losses by definition
- Regulatory/statutory capital rules can limit subsidiary dividends

---

*Last updated: 2026-08-11T04:03:56.228997+00:00*